This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yoshida, K. Articles by Iwamoto, T. Search for Related Content PubMed PubMed Citation Articles by Yoshida, K. Articles by Iwamoto, T.

Quantification of Seminal Plasma Motility Inhibitor/Semenogelin in Human Seminal Plasma

TADASHI YAMASAKI

SHOICHI TAKANO

ITARU SATO

From the ^* Department of Urology, St Marianna University School of Medicine, Kawasaki, Japan; the R&D Center, Biomedical Laboratories, Kawagoe, Japan; and the Scientific Crime Laboratory, Kanagawa Prefectural Police, Yokohama, Japan.

Correspondence to: Dr Teruaki Iwamoto, Department of Urology, St Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki 216-8511, Japan (e-mail: t4iwa{at}marianna-u.ac.jp).

Semenogelin I and II (Sg I and II) are the major components of human semen coagulum. The protein is rapidly cleaved after ejaculation by the chymotrypsin-like protease prostate-specific antigen (PSA), which results in the liquefaction of the semen coagulum and the progressive release of motile spermatozoa. One of the cleavage products of the protein, a 14-kDa protein, is a sperm motility inhibitor (seminal plasma motility inhibitor [SPMI]). We developed a monoclonal antibody (mAb) that is specific to the fragment of Sgs, SPMI, and a sandwich enzyme-linked immunosorbent assay (ELISA) system for the quantification of Sgs using this mAb. Then, we measured SPMI/Sg levels in human seminal plasma from healthy male volunteers (n = 100, aged 18-24 years). The mean level of SPMI/Sg in seminal plasma was 19 ± 13 mg/mL (range, 4-68 mg/mL). Log-transformed SPMI/Sg levels were negatively correlated with the sperm motility (r = -0.229, P = .0220) and positively correlated with the total protein concentration (r = 0.793, P < .0001). This result supports that SPMI, one of the fragments of Sg, has its inhibitory effect on ejaculated spermatozoa in liquefied semen under physiological conditions.

     Key words: Sperm motility inhibitor, seminal vesicles, asthenozoospermia

This article has been cited by other articles:

				H.J. Chi, J.H. Kim, C.S. Ryu, J.Y. Lee, J.S. Park, D.Y. Chung, S.Y. Choi, M.H. Kim, E.K. Chun, and S.I. Roh Protective effect of antioxidant supplementation in sperm-preparation medium against oxidative stress in human spermatozoa Hum. Reprod., May 1, 2008; 23(5): 1023 - 1028. [Abstract] [Full Text] [PDF]

				J. Martinez-Heredia, S. de Mateo, J. M. Vidal-Taboada, J. L. Ballesca, and R. Oliva Identification of proteomic differences in asthenozoospermic sperm samples Hum. Reprod., April 1, 2008; 23(4): 783 - 791. [Abstract] [Full Text] [PDF]

				N. Kawano and M. Yoshida Semen-Coagulating Protein, SVS2, in Mouse Seminal Plasma Controls Sperm Fertility Biol Reprod, March 1, 2007; 76(3): 353 - 361. [Abstract] [Full Text] [PDF]

				R. D. Motrich, M. Maccioni, R. Molina, A. Tissera, J. Olmedo, C. M. Riera, and V. E. Rivero Reduced semen quality in chronic prostatitis patients that have cellular autoimmune response to prostate antigens Hum. Reprod., September 1, 2005; 20(9): 2567 - 2572. [Abstract] [Full Text] [PDF]